Business
Knight and TherapeuticsMD Announce Health Canada Approval of IMVEXXY®
MONTREAL & BOCA RATON, Fla.--(BUSINESS WIRE)-- Knight Therapeutics Inc. (TSX: GUD) (“Knight”) and TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD”)
About this update from Therapeuticsmd, Inc.
[{"type":"text","content":" MONTREAL & BOCA RATON, Fla.--(BUSINESS WIRE)--\nKnight Therapeutics Inc. (TSX: GUD) (“Knight”) and TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD”) announced today the approval of IMVEXXY® by Health Canada. In Canada, IMVEXXY is for the treatment of postmenopausal moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy (VVA). VVA is a prevalent, chronic, and progressive condition associated with menopause. Common symptoms of VVA include dryness, discomfort, and pain in the vaginal and vulvar areas1-4. IMVEXXY is an applicator-free, estradiol softgel vaginal capsule indicated for postmenopausal women who experience pain before, during or after sex. IMVEXXY (estradiol vaginal inserts) is marketed by TherapeuticsMD in the U.S. for the treatment of moderate to severe dyspareunia, a symptom of VVA, due to menopause.\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200825005037/en/\n\n“IMVEXXY offers a new option for postmenopausal women to address their unmet medical needs and helps manage the suffering associated with a very bothersome and painful VVA symptom that significantly impacts quality of life,” said Samira Sakhia, President and Chief Operating Officer of Knight Therapeutics.\n\n\n“The approval of IMVEXXY by Health Canada marks a significant new milestone for Knight and we could not be more pleased as they bring this new treatment option to women in Canada,” said Robert Finizio, Chief Executive Officer of TherapeuticsMD.\n\n\nKnight and TherapeuticsMD signed a licensing agreement in July 2018 pursuant to which TherapeuticsMD granted Knight the exclusive Canadian commercialization rights to IMVEXXY and BIJUVA® (estradiol and progesterone) capsules. Under the terms of the licensing agreement related to IMVEXXY in Canada, Knight will pay TherapeuticsMD a milestone fee for the regulatory approval in Canada of IMVEXXY, sales milestone fees based upon certain aggregate annual sales of IMVEXXY in Canada, and royalties based on aggregate annual sales of IMVEXXY in Canada.\n\n\nAbout IMVEXXY\n\n\nIMVEXXY (estradiol vaginal inserts) was developed and approved in the U.S. for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.\n\n\nIMVEXXY is the only product in its therapeutic class to offer a 4 m...